中国肺癌杂志2024，Vol.27Issue(4)：306-320,15.DOI:10.3779/j.issn.1009-3419.2024.101.10
非小细胞肺癌免疫检查点抑制剂假性进展的研究进展
Advances in Pseudoprogression of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer
摘要
Abstract
The advent of immune checkpoint inhibitors(ICIs)has greatly improved the prognosis of advanced lung cancer patients,but can lead to pseudoprogression(PsP),which complicates clinical evaluation and management.PsP is manifested as temporary enlargement of the tumour or the appearance of new lesions,etc.,and improvement in imaging occurs with continued treatment,mostly without worsening of clinical symptoms.Currently,there are still difficulties in the early diag-nosis of PsP,and its occurrence mechanism is not yet clear,lacking good predictive factors and related biomarkers.This article reviews the current research status of PsP of ICIs in non-small cell lung cancer in order to provide helpful clinical strategies for oncologists using these drugs.关键词
肺肿瘤/免疫检查点抑制剂/假性进展/免疫治疗Key words
Lung neoplasms/Immune checkpoint inhibitors/Pseudoprogression/Immunotherapy引用本文复制引用
童亚军,龙咏,张帆,李军烽..非小细胞肺癌免疫检查点抑制剂假性进展的研究进展[J].中国肺癌杂志,2024,27(4):306-320,15.基金项目
This paper was supported by the grant from 2020 Wu Jieping Medical Foundation(No.320.6750.2020-10-34)(to Junfeng LI). 本文受2020年吴阶平医学基金会(No.320.6750.2020-10-34)资助 （No.320.6750.2020-10-34）
